Navigation Links
Nektar Announces that FDA Grants Fast Track Designation to Etirinotecan Pegol (NKTR-102) for the Treatment of Metastatic Breast Cancer
Date:11/7/2012

didate for chronic pain conditions, is in Phase 2 development in osteoarthritis patients with chronic knee pain. NKTR-192, a novel mu-opioid analgesic in development to treat acute pain is in Phase 1 clinical development. In oncology, etirinotecan pegol (NKTR-102) is being evaluated in a Phase 3 clinical study (the BEACON study) for the treatment of metastatic breast cancer and is also in Phase 2 studies for the treatment of ovarian and colorectal cancers.

Nektar's technology has enabled eight approved products in the U.S. or Europe through partnerships with leading biopharmaceutical companies, including Affymax's OMONTYS® for anemia, UCB's Cimzia® for Crohn's disease and rheumatoid arthritis, Roche's PEGASYS® for hepatitis C and Amgen's Neulasta® for neutropenia. Additional development-stage products that leverage Nektar's proprietary technology platform include Baxter's BAX 855, a long-acting PEGylated rFVIII program, which has completed Phase 1/2 clinical development.

Nektar is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama and Hyderabad, India. Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com.

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.  Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "expect," "believe," "should," "could," "potential," "may" and similar references to future periods.  Examples of forward-looking statements include our current views as to the potential of etirinotecan pegol as a potential new therapy for patients with metastatic breast cancer; the expected enrollment completion date for the BEACON trial; the value of our polymer conjugate technology platform; and the potential of
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Nektar to Announce Financial Results for the Third Quarter of 2012 On Tuesday, November 13, 2012, After Close of U.S.-Based Financial Markets
2. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the UBS 2012 Global Life Sciences Conference in New York City
3. Nektar Therapeutics Reports Financial Results for the Second Quarter of 2012
4. Nektar Announces Initiation of Investigator-Sponsored Trial Evaluating Etirinotecan Pegol (NKTR-102) in Patients with Bevacizumab (Avastin)-resistant High-Grade Glioma
5. Nektar Announces Start of Enrollment in Phase 2 Study of NKTR-181, a Novel Opioid Analgesic Molecule, for Treatment of Chronic Pain
6. Nektar Announces that FDA Grants Fast Track Designation to NKTR-181, a New Oral Opioid Analgesic Molecule, for the Treatment of Moderate to Severe Chronic Pain
7. Nektar Therapeutics President and CEO Howard W. Robin to Present at the Jefferies 2012 Global Healthcare Conference in New York
8. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
9. Nektar to Announce Financial Results for the First Quarter of 2012 on Wednesday, May 2, 2012, After Close of U.S.-Based Financial Markets
10. Life Technologies Announces Next-Gen Digital PCR Instrument Designed for Widespread Adoption
11. Blue Belt Technologies Announces First United Kingdom-Based NavioPFS Unicondylar Knee Replacement Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... July 20, 2015 ... the addition of the "Cardiometabolic Drug News ... Afrezza,s discounted pricing is in line with our ... to the product,s commercial appeal. However, contraindications, side ... from gaining a sizeable share of the fast-acting ...
(Date:7/27/2015)... N.H. , July 27, 2015  Linear ... incredibly intricate machines, requiring not only adequate space ... vaults for their operation. Inherent to the size ... a linear accelerator or the addition of a ... hospital. Suspending operations risks interruption of patient treatment: ...
(Date:7/27/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/65t478/gprotein_coupled ) has ... Receptors Market: Global Industry Analysis, Size, Share, Growth, ... to their offering. The global ... assay type, therapeutic area, and geography. Based on ... into six major segments: cAMP assays, calcium level ...
Breaking Medicine Technology:Cardiometabolic Drug News Issue - Afrezza Aggressive Pricing Strategy View Playing Out 2Cardiometabolic Drug News Issue - Afrezza Aggressive Pricing Strategy View Playing Out 3Accelerating the Design Process for Cancer Treatment Centers 2Accelerating the Design Process for Cancer Treatment Centers 3G-Protein Coupled Receptors Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2022 2
... Pharma NV/SA, a rapidly growing pharmaceutical company specialising in ... Veeva CRM to support its salesforce in Belgium. Pharco ... application that was both pharma-specific and easily adaptable. The ... for the global pharma and biotech industry. ...
... New Zealand health technology company Medtech Global, ... collaborated to develop an electronic health information solution ... medical records of visiting international MedicAlert members in ... first" the long term vision for the solution ...
Cached Medicine Technology:Pharco Pharma NV/SA Leverages Advantages of Cloud Computing With the Implementation of Veeva CRM 2Pharco Pharma NV/SA Leverages Advantages of Cloud Computing With the Implementation of Veeva CRM 3Medtech and MedicAlert Create Global Connection for Rugby World Cup 2011 2Medtech and MedicAlert Create Global Connection for Rugby World Cup 2011 3
(Date:7/27/2015)... ... July 27, 2015 , ... ... One, **FDAnews Webinar**, Aug. 13, 2015 — 1:30 p.m. – 3:00 p.m. EDT, ... the first things FDA investigators will look at during an inspection. Yet, ...
(Date:7/27/2015)... ... 27, 2015 , ... On July 14, 2015, Harper’s Bazaar Magazine in an ... skin issues such as stretch marks , fine lines , and ... treatment options listed include lasers, ultrasound, radio frequency, Botox, and dermal fillers. It is ...
(Date:7/27/2015)... ... July 27, 2015 , ... North Central Surgical Center Hospital ... The center invites all those prospective joint-replacement patients, along with their friends and family ... month, with Monday classes (Aug 6, Sept 8 [Tue due to Labor Day], Oct ...
(Date:7/27/2015)... , ... July 27, 2015 , ... David Gilmour ... He will be performing for one additional night at each of his original four ... DAVID-GILMOUR-2016 for added savings. , David Gilmour’s 2016 North America tour dates: , Thursday, ...
(Date:7/27/2015)... ... July 27, 2015 , ... In an ongoing program of ... its options. Already an industry leader because of its use of iPad technology ... latest successful trends in helping people to overcome addiction and live healthy, productive ...
Breaking Medicine News(10 mins):Health News:FDAnews Announces — Writing Effective Standard Operating Procedures: Ensure Quality and Compliance From Step One Webinar, Aug. 13, 2015 2Health News:FDAnews Announces — Writing Effective Standard Operating Procedures: Ensure Quality and Compliance From Step One Webinar, Aug. 13, 2015 3Health News:FDAnews Announces — Writing Effective Standard Operating Procedures: Ensure Quality and Compliance From Step One Webinar, Aug. 13, 2015 4Health News:The Latest Treatment Options for Seven Common Skin Issues 2Health News:North Central Surgical Center Hospital to Hold Joint Wellness Classes 2Health News:Cheap David Gilmour Tickets at Madison Square Garden (MSG), Air Canada Center, United Center and Hollywood Bowl: Additional Dates for David Gilmour Go On Sale Today 2Health News:Hiking Adds Benefits to Recovery at Serenity Palms 2Health News:Hiking Adds Benefits to Recovery at Serenity Palms 3
... says more programs needed for transition to adult health care ... arthritis need more help and information when they approach adulthood ... new study shows. , The study, led by Peter Scal ... of adolescents with arthritis received counseling on issues such as ...
... Drain NEW YORK, Jan. 13 New York Blood ... City, Long Island, Hudson Valley and New Jersey) have ... demand for blood (needed for emergency care and surgery) ... donation have been below forecast. Blood supplies have ...
... Goldring smiles as she shows a visitor photos she,s taken ... The demonstration comes more than 20 years after Goldring, a ... colleagues began work on a "seeing machine" that can allow ... the Internet, view the face of a friend and much ...
... New Version Increases Physician AccessSUNNYVALE, Calif., Jan. 13 ... version of the Pathwork(R) Tissue of Origin Test ... (FFPE) tissue specimens. This molecular diagnostic test, which ... origins, is now available as a service through ...
... 13, 2009) The American Journal of Nursing ... healthcare publications of 2008 with an announcement today of ... 15 separate categories appear in the journal,s January issue. ... of controversial consumer health topics and nursing industry issues ...
... Fla., Jan. 13 Zassi Medical,Evolutions(R), a privately ... and development, today announced the launch of e-Zassi(TM) ... the medical,device industry by streamlining diligence, collaboration and ... an exclusive array of,intelligent Web-based applications. , ...
Cached Medicine News:Health News:Blood Emergency: Blood Supply Tips Into Danger Zone 2Health News:Blood Emergency: Blood Supply Tips Into Danger Zone 3Health News:Blood Emergency: Blood Supply Tips Into Danger Zone 4Health News:Blood Emergency: Blood Supply Tips Into Danger Zone 5Health News:MIT develops camera for the blind 2Health News:Pathwork Diagnostics Launches Version of Its Tissue of Origin Test for FFPE Specimens 2Health News:Pathwork Diagnostics Launches Version of Its Tissue of Origin Test for FFPE Specimens 3Health News:American Journal of Nursing announces 2008 Book of the Year Awards 2Health News:Zassi Medical Evolutions Launches New Online Company That Uses 'Business DNA' to Deliver Advanced Discovery, Collaboration, and Business Intelligence Tools to the Medical Device Industry 2Health News:Zassi Medical Evolutions Launches New Online Company That Uses 'Business DNA' to Deliver Advanced Discovery, Collaboration, and Business Intelligence Tools to the Medical Device Industry 3
... The SYNCHRON CX5-S workstation ... electrolyte testing, targeted to the ... than 200 samples per day. ... the CX5-S is easy to ...
... the high-volume lab, the SYNCHRON LX4201 simplifies ... up to 2,880 tests per hour. By ... SYNCHRON LX4201 with broad menu, speed and ... come to expect from Beckman Coulter-innovative, reliable ...
... It takes powerful technology to ... safety, and still lower costs. ... LX20 PRO, offering features that ... any other chemistry analyzer, including ...
... the power of the LX2000 Series ... resources without compromising testing quality.Plus, when ... LX20 PRO, you get advanced features ... other chemistry analyzer, including closed tube ...
Medicine Products: